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The cancer database used by the U.S.
Environmental Protection Agency (EPA) and
other agencies for risk assessment for expo-
sure to carcinogens focuses on adults and
adult exposures. Much cancer epidemiology
comes from occupational studies and rodent
cancer studies, which were designed to last
approximately a lifetime (2 years) beginning
after sexual maturity. Cancer risks from
childhood exposures to chemicals are gener-
ally analyzed using methods based on expo-
sure to adults, which assumes chemicals are
equally potent for inducing risks of exposures
in both early life and later life. Animal and
human data suggest that further analysis is
warranted to determine whether early-life
exposure results in increased susceptibility to
cancer compared with adult exposures
(Anderson et al. 2000; National Research
Council 1993). There is extensive literature
demonstrating that exposures early in life (i.e.,
transplacental or in utero, early postnatal, and
lactational) in animals can result in the devel-
opment of cancer (reviewed in Anderson et al.
2000; Della Porta and Terracini 1969;
Druckrey 1973; Rice 1979; Rice and Ward
1982; Toth 1968; Vesselinovitch 1983;
Vesselinovitch et al. 1979a). However, except
for data on radiation and prenatal exposure to
diethylstilbesterol (DES), there are virtually
no human data adequate for quantitative
analysis.
Standard animal bioassays generally begin
dosing after the animals are 6–8 weeks of age,
when many organs and systems are relatively
mature, although substantial growth in body
size continues thereafter. Reviews comparing
perinatal carcinogenesis bioassays with standard
bioassays for a limited number of chemicals
(McConnell 1992; U.S. EPA 1996) have con-
cluded that the same tumor sites usually are
observed after either perinatal or adult expo-
sure, and that perinatal exposure in conjunc-
tion with adult exposure usually increases the
incidence of tumors or reduces the latent
period before tumors are observed.
There is limited evidence to inform the
mode(s) of action leading to differences in
tumor type and tumor incidence after early-life
exposure compared with exposure later in life.
Differences in the capacity to metabolize and
clear chemicals at early ages can result in larger
or smaller internal doses of the active agent(s),
either increasing or decreasing risk (Ginsberg
et al. 2002; Renwick 1998). Mechanistic data
supporting early-life susceptibility to DNA
damaging mutagenic chemicals include
increased formation of DNA adducts after
exposure to vinyl chloride (Laib et al. 1989;
Morinello et al. 2002a, 2002b), increased
induction of micronuclei in fetal tissues
(Hayashi et al. 2000), and increased mutations
in brains of transgenic mice exposed to ethyl-
nitrosourea (ENU; Slikker et al. 2004). The
neonatal mouse model for carcinogenesis,
which uses two doses before weaning followed
by observation of tumors at 1 year, shows car-
cinogenic responses for mutagenic carcinogens
(Flammang et al. 1997; Fujii 1991; McClain
et al. 2001).
Current understanding of biologic
processes involved in carcinogenesis leads to a
reasonable expectation that children are more
susceptible to some carcinogenic agents than
adults (Anderson et al. 2000; Birnbaum and
Fenton 2003; Ginsberg 2003; Miller et al.
2002; Scheuplein et al. 2002). Several aspects
potentially lead to increased childhood sus-
ceptibility. More frequent cell division during
development can result in enhanced fixation
of mutations because of the reduced time
available for repair of DNA lesions, and
clonal expansion of mutant cells gives a larger
population of mutants (Slikker et al. 2004).
Some components of the immune system are
not fully functional during development
(Holladay and Smialowicz 2000; Holsapple
et al. 2003). Hormonal systems operate at
different levels during various life stages
(Anderson et al. 2000). Induction of develop-
mental abnormalities may result in a pre-
disposition to carcinogenic effects later in life
(Birnbaum and Fenton 2003; Fenton and
Davis 2002).
Finally, theoretical analyses suggest
that differential susceptibility would depend,
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Cancer risk assessment methods currently assume that children and adults are equally susceptible to
exposure to chemicals. We reviewed available scientific literature to determine whether this was scien-
tifically supported. We identified more than 50 chemicals causing cancer after perinatal exposure.
Human data are extremely limited, with radiation exposures showing increased early susceptibility at
some tumor sites. Twenty-seven rodent studies for 18 chemicals had sufficient data after postnatal and
adult exposures to quantitatively estimate potential increased susceptibility from early-life exposure,
calculated as the ratio of juvenile to adult cancer potencies for three study types: acute dosing,
repeated dosing, and lifetime dosing. Twelve of the chemicals act through a mutagenic mode of
action. For these, the geometric mean ratio was 11 for lifetime exposures and 8.7 for repeat exposures,
with a ratio of 10 for these studies combined. The geometric mean ratio for acute studies is 1.5, which
was influenced by tissue-specific results [geometric mean ratios for kidney, leukemia, liver, lymph,
mammary, nerve, reticular tissue, thymic lymphoma, and uterus/vagina > 1 (range, 1.6–8.1);
forestomach, harderian gland, ovaries, and thyroid < 1 (range, 0.033–0.45)]. Chemicals causing cancer
through other modes of action indicate some increased susceptibility from postnatal exposure (geo-
metric mean ratio is 3.4 for lifetime exposure, 2.2 for repeat exposure). Early exposures to compounds
with endocrine activity sometimes produce different tumors after exposures at different ages. These
analyses suggest increased susceptibility to cancer from early-life exposure, particularly for chemicals
acting through a mutagenic mode of action. Key words: cancer, children, early-life exposure, exposure,
mode of action, risk assessment, susceptible populations. Environ Health Perspect 113:1125–1133
(2005). doi:10.1289/ehp.7667 available via http://dx.doi.org/ [Online 7 April 2005]
Review
in part, on the mode of action [i.e., at what
step in the cancer process(es) the chemical
was acting] and that the lifetime average daily
dose may underestimate or overestimate the
cancer risk when exposures are time depen-
dent (Goddard and Krewski 1995; Murdoch
et al. 1992).
We reviewed the available scientific litera-
ture to determine the extent of potential
increased susceptibility from early-life expo-
sure. We evaluated potential susceptibility by
individual study and tumor type rather than a
combined analysis of all data by certain cate-
gories (e.g., gender) (Hattis et al. 2004).
Further supporting evidence from ionizing
radiation is given in the Appendix (http://
ehp.niehs.nih.gov/docs/2005/7667/app.pdf).
Although there is evidence showing that prena-
tal exposures can result in tumors later in life
(Anderson et al. 2000; Birnbaum and Fenton
2003; Diwan et al. 1992; Hatch et al. 1998;
Waalkes et al. 2003), this analysis focuses only
on exposures in animals occurring postnatally
up to approximately 5–8 weeks of age.
Materials and Methods
Procedures
Data sources for animal studies. We identi-
fied initial studies for consideration through
review articles and a search of the National
Toxicology Program database (NTP 2003). A
literature search was conducted using key
words and MeSH headings from the PubMed
database (PubMed 2004) from studies identi-
fied in the available reviews. The chemicals
considered and then included for quantitative
evaluation are listed in Table 1 and in
Supplementary Table S1 (http://ehp.niehs.nih.
gov/docs/2005/7667/sup.pdf).
We reviewed abstracts or papers to deter-
mine if a study provided information that
could be used for quantitative analysis based
on the following criteria:
• Exposure groups at different postnatal ages
in the same study or same laboratory, if not
concurrent (to control a large number of
potential cross-laboratory experimental vari-
ables including pathologic examinations)
• Same strain/species (to eliminate strain-
specific responses confounding age-dependent
responses)
• Approximately the same dose within the
limits of diets, and drinking water intakes
that obviously can vary with age (to elimi-
nate dose-dependent responses confounding
age-dependent responses).
• Similar or identical period for tumor expres-
sion after exposures at different ages—
variations of around 10–20% in time to
sacrifice are acceptable arising from sacrifice
at > 1 year for all groups exposed at different
ages, where early-life exposure can occur up
to about 7 weeks (to control for confounding
differential periods for tumor expression with
age-dependent changes in tumor incidences).
• Postnatal exposure for juvenile rats and
mice at ages younger than the standard
6–8 week start for bioassays; studies that
have postnatal exposure were included even
if they also involved prenatal exposure, but
studies with only prenatal (in utero) expo-
sures are not part of the present analysis.
• “Adult” rats and mice exposure beginning at
approximately 6–8 weeks of age, that is,
comparable with the age at initiation of a
standard cancer bioassay. Studies in other
species were used as supporting evidence,
because they are relatively rare and the
determination of the appropriate compari-
son ages across species is not simple.
• Number of affected animals and total num-
ber of animals examined must be available or
reasonably reconstructed for control, young,
and adult groups (i.e., studies reporting only
percent response or not including a control
group would be excluded unless a reasonable
estimate of historical background for the
strain was obtainable).
Supplementary Tables S2 and S3 (http://
ehp.niehs.nih.gov/docs/2005/7667/supp.pdf)
include information used for the calculations.
Pertinent information on species, sex, dosing
regimen, and tumor incidence is given.
The literature includes studies that can be
divided roughly into three types of exposure
scenarios (Figure 1): repeated exposures for the
early postnatal to juvenile period compared
with chronic later-life dosing; lifetime (i.e.,
combined perinatal and adult) exposure com-
pared with chronic later-life dosing; and acute
exposures such as a single intraperitoneal or
subcutaneous injection for both early-life and
later-life dosing.
Evaluating the mode of action of carcino-
gens. Chemicals were classified into categories
based on evaluating the mode of action using
a weight-of-evidence approach. Determination
of carcinogens that are operating by a muta-
genic mode of action entails evaluation of
short-term testing results for genetic end
points, metabolic profiles, physicochemical
properties, and structure–activity relationship
Barton et al.
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Table 1. List of chemicals considered in the quantitative analysis for which there are both early-life and
adult exposure reported in the same animal experiment.
Mutagenic
Chemical References Study type mode of action
Amitrole Vesselinovitch 1983 Repeat dosing
Benzidine Vesselinovitch et al. 1975b Repeat dosing X
Benzo[a]pyrene Vesselinovitch et al. 1975a Acute exposure X
Dibenzanthracene Law 1940 Acute exposure X
Dichlorodiphenyltrichloroethane Vesselinovitch et al. 1979a Repeat dosing
Lifetime exposure
Dieldrin Vesselinovitch et al. 1979a Repeat dosing
Lifetime exposure
Diethylnitrosamine Peto et al. 1984 Lifetime exposure X
Vesselinovitch et al. 1984 Acute exposure
Dimethylbenz[a]anthracene Meranze et al. 1969 Acute exposure X
Pietra et al. 1961 Acute exposure
Walters 1966 Acute exposure
Dimethylnitrosamine Hard 1979 Acute exposure X
Diphenylhydantoin, 5,5- Chhabra et al. 1993b Repeat dosing
Lifetime exposure
Ethylnitrosourea Naito et al. 1981 Acute exposure X
Vesselinovitch et al. 1974 Acute exposure
Vesselinovitch 1983 Acute exposure
Ethylene thiourea Chhabra et al. 1992 Repeat dosing
Lifetime exposure
3-Methylcholanthrenea Klein 1959 Repeat dosing X
N-Methylnitrosourea Terracini and Testa 1970 Acute exposure
Terracini et al. 1976 Acute exposure X
Polybrominated biphenyls Chhabra et al. 1993a Repeat dosing
Lifetime exposure
Safrole Vesselinovitch et al. 1979a Repeat dosing
Lifetime exposure X
Urethane Chieco-Bianchi et al. 1963 Acute exposure X
Choudari Kommineni et al. 1970 Acute exposure
De Benedictis et al. 1962 Acute exposure
Fiore-Donati et al. 1962 Acute exposure
Klein 1966 Acute exposure
Lifetime exposure
Liebelt et al. 1964 Acute exposure
Rogers 1951 Acute exposure
Vinyl chloride Maltoni et al. 1984 Repeat dosing X
X, chemicals with a mutagenic mode of action. The chemicals listed here are from the list of more than 50 chemicals
found to have carcinogenic effects from prenatal or postnatal exposures in animals [Supplementary Table S1
(http://ehp.niehs.nih.gov/docs/2005/7667/supp.pdf)]. 
aFormerly known as 20-methylcholanthrene.
(SAR) analyses in a weight-of-evidence
approach (Dearfield et al. 1991; U.S. EPA
1986, 1991; Waters et al. 1999), as has been
done for several chemicals (e.g., Dearfield
et al. 1999; McCarroll et al. 2002; U.S. EPA
2000). Key data for a mutagenic mode of
action may be evidence that the carcinogen or
a metabolite is DNA reactive and/or has the
ability to bind to DNA. Also, mutagenic car-
cinogens usually produce positive effects in
multiple test systems for different genetic end
points, particularly gene mutations, and in
tests performed in vivo that generally are sup-
ported by positive tests in vitro. Additionally,
carcinogens may be identified as operating via
a mutagenic mode of action if they have prop-
erties and SARs similar to those of established
mutagenic carcinogens. Those with a muta-
genic mode of action are identified in Table 1.
Quantitative Methods
To estimate the potential difference in suscepti-
bility between early-life and adult exposure, we
calculated the ratio of the estimated cancer
potency from early-life exposure compared with
the estimated cancer potency from adult expo-
sure. The cancer potency was estimated from a
one-hit model, or a restricted form of the
Weibull model, which is commonly used to
estimate cumulative incidence for tumor onset.
The general form of the equation is as follows:
P(dose) = P(0) +[1 – P(0)]
[1 – exp(–cancer potency × dose)].
Juvenile and adult cancer potencies and the
ratio of the two were calculated by fitting this
model to the data for each age group. The
model fit depended upon the design of the
experiment that generated the data. Two
designs need to be handled separately: repeat
and acute exposure and lifetime exposures.
For the first case, the model equations are
as follows:
[1]
where subscripts A and J refer to the adult and
juvenile period, respectively; λ is the natural
logarithm of the juvenile:adult cancer potency
ratio; P0 is the fraction of control animals with
the particular tumor type being modeled; Px is
the fraction of animals exposed in age period x
with the tumor; mA is the cancer potency, the
rate of accumulation of “hits” per unit of time
for adults; and δx is the duration or number of
exposures during age period x. For a substantial
number of data sets (acute exposures), δJ =δA = 1. We are interested in determining λ,
which is the logarithm of the estimated ratio of
juvenile to adult cancer potencies, a measure of
potential susceptibility for early-life exposure.
For the lifetime exposures, the model
equations need to take into account that expo-
sures were initiated in the juvenile period con-
tinue through the adult period. The model
equations for the fraction of animals exposed
only as adults with tumors in this design is the
same as in the first design, but the fraction of
animals whose first exposure occurred in the
juvenile period is
[2]
All symbols in Equation 2 have the same
interpretation as their counterparts in
Equation 1, but now δJ includes the duration
of exposure during the juvenile period as well
as the subsequent adult period.
Parameters mA and λ in these models were
estimated using Bayesian methods ( e.g., see
Carlin and Louis 2000), and all inferences
about the ratios were based on the marginal
posterior distribution of λ. The data for esti-
mating each ratio were in the form of numbers
of animals tested and number affected for each
of control, juvenile-exposed, and adult-
exposed animals, and duration of exposure for
each of the juvenile-exposed and adult-
exposed groups. A few data sets had separate
control groups for the juvenile-exposed and
adult-exposed groups, and Equations 1 and 2
were modified accordingly. The likelihood for
the parameters mA and λ in the model was the
product of three (or four, if there were two
control groups) binomial probabilities: the
number of animals with tumors in the adult
control group, in the juvenile control group,
in the juvenile-exposed group, and in the
adult-exposed group. The prior for P0 (the
fraction of control animals with a particular
tumor) was right triangular, which assumes
incidences should be relatively low. The effect
of exposure in adults is quantified by the extra
risk, Q, where the probability that an animal
has a tumor is P0 + (1 – P0)Q. So, from
Equation 1, Q was given a uniform prior on
the interval (0,1), reflecting total ignorance
about the extra risk of adult exposure. Finally,
the prior for λ was Gaussian with mean 0 (cor-
responding to a median or geometric mean
ratio of 1) and standard deviation of 3. The
prior for the log ratio has some influence over
the posterior estimates for the ratio of juvenile
to adult potency. The magnitude of that influ-
ence depends on the amount of support in the
data for different values of the log ratio. This
potential influence is further discussed with
illustrations in the Appendix (http://ehp.niehs.
nih.gov/docs/2005/7667/app.pdf).
To examine the sensitivity of the estimates
to choice of the prior, values were re-estimated
using a prior with a larger standard deviation.
This was initially chosen to be 9, but for some
of the lifetime exposure and acute exposure
studies, a standard deviation of 9 led to
numerical problems integrating the posterior,
so a prior with a standard deviation of 6 was
used in these cases. Sensitivity to the choice of
prior was evaluated by looking at changes of
individual log ratios and their variances and
through differences in geometric means.
The posterior distribution for the unknown
parameters in these models is the product of
the likelihood from the data and the priors
(the “unnormalized” prior), divided by a nor-
malization constant that is the integral of the
unnormalized prior over the ranges of all the
parameters. This normalization constant was
computed using numerical integration, as
were posterior means and variances and mar-
ginal posterior quantiles for the log ratio λ. All
numerical computations were carried out in
the R statistical programming language (ver-
sion 1.8.1; R Development Core Team 2003).
This method produced a posterior mean
of ratio of the early-life to adult cancer
potency, which is an estimate of the potential
susceptibility of early-life exposure to carcino-
gens. Ratios > 1 indicated greater susceptibility
from early-life exposure. Ratios < 1 indicated
less susceptibility from early-life exposure.
Summaries of the individual ratios from each
P P P eJ
mAe J A mA A= + +( )( − )−( )0 01 1 – – .
λ δ δ δ
P P P e
P P P e
A
mA A
J
mAe
= + ( )( − )
= + ( )( −
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0 0
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1 1
–
–
–
–
δ
λδ J ),
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Standard rodent cancer study: adult exposure
*Postnatal exposure
*Postnatal and adult exposure (lifetime)
Animal lifespan
Mating
Birth
Weaning
Puberty Lifetime of tumors
(typically 2 years)
Lifetime
comparison
Repeated
dosing
comparison
Figure 1. Schematic representation of several cancer study designs reported in the evaluated literature.
The standard rodent bioassay begins after puberty, and exposures continue for about 2 years. Repeated-
dosing studies typically dose during the postnatal period, with observations for tumors at approximately
2 years. Lifetime studies combine postnatal and adult exposures, sometimes beginning with in utero expo-
sure. Acute studies (not shown) generally involve one or a few exposure during the in utero, preweaning,
prepubertal, and adult periods. The adult tumors were often evaluated much earlier than 2 years. 
*Can also include prenatal exposure.
of the dose groups from the different experi-
ments for different groupings were also calcu-
lated (e.g., for all acute mutagenic chemicals).
The summary ratios were constructed from
the individual ratios within a group by inverse
variance-weighting the means of each ratio.
The individual means were weighted by using
reciprocals of posterior variances, so ratios
with more variance were given less weight in
the summary ratios. Exponentiating the result-
ing variance-weighted mean yielded variance-
weighted geometric means of ratios.
Results
A review of the literature identified several
hundred references reporting more than
50 chemicals able to cause cancer after perina-
tal exposure in animals [Supplementary
Table S1 (http://ehp.niehs.nih.gov/docs/
2005/7667/supp.pdf)]. Often, these studies
demonstrated carcinogenesis after perinatal
exposure but did not directly compare expo-
sures in adults. A large number of studies
address in utero exposures only. Studies across
laboratories often varied in their use of animal
strains [e.g., for 3´-azido-3´-deoxythymidine
(AZT) studies, Diwan et al. (1999) used CD-1
mice, whereas the National Toxicology
Program (NTP 1999) used B6C3F1 mice] or
had different periods of tumor follow-up (e.g.,
tamoxifen and uterine tumors in Carthew et al.
2000). Because of these factors, many of these
chemicals in Supplementary Table S1
(http://ehp.niehs.nih.gov/docs/2005/7667/
supp.pdf) were not evaluated quantitatively.
Studies assessing radiation in animals exist, but
lack of uniformity regarding radiation doses,
gestational age at exposure, and the animal
strains used make it difficult to make compari-
sons across studies (Preston et al. 2000).
Some of the studies that did not have suf-
ficient information for quantitative evaluation
provide important supporting information for
early-life susceptibility. Increased multiplicity
of colon tumors was observed after earlier ver-
sus later azoxymethane exposures (Paulsen
et al. 2003). Shortened mammary tumor
latency after estradiol exposure occurred for
Barton et al.
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Table 2. Ratio of early-life to adult cancer potencies for studies with repeat exposures of juvenile and adult animals to mutagenic chemicals. 
Ratio of juvenile to adult cancer potency
Species, Geometric
Compound strain Sex Dose Tumor mean 2.5% Median 97.5% Reference
Benzidine Mice Male Liver 111 64 110 198 Vesselinovitch et al. 1975b
(B6C3F1) Female Liver 0.16 0.004 0.22 1.1
3-Methylcholanthrenea Mice Male 0.25 mg/g Hepatoma 33 7.4 30 268 Klein 1959
(albino) Female 0.25 mg/g Hepatoma 7.7 1.1 7.1 85
Male 0.25 mg/g Forestomach 0.91 0.39 0.91 2.1
Female 0.25 mg/g Forestomach 1.5 0.58 1.5 4.2
Male 0.25 mg/g Skin 1.8 0.048 2.1 22
Female 0.25 mg/g Skin 1.5 0.023 1.8 21
Safrole Mice Male Liver 46 16 44 198 Vesselinovitch et al. 1979b
(B6C3F1) Female Liver 0.12 0.002 0.18 1.1
Vinyl chlorideb Rats Male 10,000 ppm Liver angiosarcoma 7.4 0.035 11 62 Maltoni et al. 1984
(Sprague-
Dawley) Female 10,000 ppm Liver angiosarcoma 30 8.7 29 121
Male 10,000 ppm Zymbal gland 0.27 0.0022 0.4 5.4
Female 10,000 ppm Zymbal gland 0.15 0.0014 0.19 4.5
Male 10,000 ppm Leukemia 21 0.026 37 514
Female 10,000 ppm Leukemia 0.29 0.0019 0.35 17
Male 10,000 ppm Nephroblastomas 0.17 0.0015 0.21 6.2
Female 10,000 ppm Nephroblastomas 0.24 0.0017 0.29 11
Male 10,000 ppm Angiosarcomas 0.25 0.0017 0.30 12
other sites
Female 10,000 ppm Angiosarcomas 0.32 0.0019 0.38 20
other sites
Male 10,000 ppm Angiomas and fibromas 1.4 0.0045 2.36 47
other sites
Female 10,000 ppm Angiomas and fibromas 0.52 0.0024 0.63 41
other sites
Male 10,000 ppm Hepatoma 34 8.2 32 218
Female 10,000 ppm Hepatoma 55 8.4 53 513
Male 10,000 ppm Skin carcinomas 0.41 0.0024 0.56 15
Female 10,000 ppm Skin carcinomas 0.31 0.0019 0.37 19
Male 10,000 ppm Neuroblastoma 0.20 0.0016 0.24 8.5
Female 10,000 ppm Neuroblastoma 0.14 0.0014 0.18 4.4
aFormerly known as 20-methylcholanthrene. bResults for 6,000 ppm are similar to those for 10,000 ppm and are given in Supplementary Table S4 (http://ehp.niehs.nih.gov/docs/2005/7667/
supp.pdf).
Table 3. Ratio of early-life to adult cancer potencies for studies with lifetime exposures starting with juvenile and adult, for chemicals acting through a mutagenic
mode of action.
Ratio of juvenile to adult cancer potency
Species, Geometric
Compound strain Sex Dose Tumor mean 2.5% Median 97.5% References
Diethylnitrosamine Rats Multiple Liver 2.8 0.0093 5.6 23 Peto et al. 1984
(Colworth) Esophagus 0.18 0.0015 0.23 4.8
Safrole Mice Male Liver 46 3.7 50 253 Vesselinovitch et al. 1979b
(B6C3F1) Female Liver 1.9 0.007 4.0 23
Urethane Mice Male 2.5 µg/g/bw Liver 79 0.36 102 1,064 Klein 1966
(B6AF1/J) Female 2.5 µg/g/bw Liver 0.47 0.0022 0.55 43
bw, body weight.
exposures between 8 and 18 weeks as opposed
to exposures earlier or later in life (Yang et al.
2003), consistent with results for dimethyl-
benz[a]anthracene (DMBA; Meranze et al.
1969). Notable examples exist of developmen-
tal windows leading to cancer susceptibilities
that were not observable in adults. Several
potent estrogens, including DES, tamoxifen,
and genistein, produce uterine tumors with
early postnatal exposures of mice, although
there also appear to be strain-dependent differ-
ences in the tumor sites in adult mice (Gass
et al. 1964; Greenman et al. 1990; Newbold
et al. 1990, 1997, 2001). Developmental sus-
ceptibilities are believed to play a key role in
effects observed with saccharin (Cohen et al.
1995; Whysner and Williams 1996) and
ascorbate (Cohen et al. 1998; NTP 1983),
with bladder tumors arising only when early-
life exposures occurred; studies with other
food additives did not find cancers after either
adult-only or combined early-life and adult
exposures (U.S. EPA 1996). Finally, central
nervous systems tumors appear highly depen-
dent upon exposures to ENU and several
other chemicals during appropriate develop-
mental windows, particularly prenatally, as
observed in several species including rat,
mouse, and opossum (Jurgelski et al. 1979;
Rice 1979; Rice and Ward 1982).
Quantitative Evaluation 
of the Database
Studies (or groups of studies from a single
laboratory on a given chemical) that provided
quantitative data were identified for 18 chemi-
cals [Table 1; Supplementary Tables S2, S3
(http://ehp.niehs.nih.gov/docs/2005/7667/
supp.pdf)]. Nine chemicals involved repeated
exposures during early postnatal and adult life
stages, eight chemicals had lifetime exposure
starting in the juvenile period and adult-only
exposure, and eight chemicals used acute
exposures (typically single doses) at different
ages (Table 1). Some studies evaluated single
tissues for tumors (e.g., only liver), whereas
others evaluated multiple tissues. Mice, rats, or
both species and sometimes multiple strains
were tested.
Carcinogens with a Mutagenic 
Mode of Action
The most informative database on early–life-
stage susceptibility exists for chemicals with a
well accepted mutagenic mode of action and
includes both acute-exposure and repeated-
exposure studies involving periods of perinatal
and/or chronic exposure.
Repeat and lifetime exposure studies
of mutagenic chemicals. Studies comparing
repeated dosing for early postnatal, juvenile,
adult time periods, or lifetime exposures
exist for six mutagens [benzidine, diethyl-
nitrosamine (DEN), 3-methylcholanthrene,
safrole, urethane, and vinyl chloride; Tables 1,
2, 3; Supplementary Table S4 (http://ehp.
niehs.nih.gov/docs/2005/7667/supp.pdf)].
DEN and urethane also had acute-dosing
studies. These chemicals all require metabolic
activation to the active carcinogenic form.
For the repeated-dosing studies, the ratios
of juvenile to adult cancer potency ranged
from 0.12 to 111 with a geometric mean ratio
of 11 (Tables 1, 2, 4; Figure 2). For the life-
time studies, the ratios ranged from 0.18 to 79
with a geometric mean of 8.7 [Tables 3, 4;
Supplementary Table S5 (http://ehp.niehs.
nih.gov/docs/2005/7667/supp.pdf); Figure 2].
The geometric mean combining the repeated
and lifetime data for six chemicals was 10
(Table 4). Calculations based upon even
broader, less informative prior distributions
(e.g., SD = 6 or 9) gave higher estimates for the
geometric means, 17 and 20, for repeated and
lifetime studies, respectively, and wider ranges
(0.0011–115.2 for repeated-dosing studies,
0.0014–157.78 for lifetime studies). The prior
estimates appear to have a greater influence on
the estimates of λ (natural log of the ratio of
juvenile to adult cancer potency) from the life-
time study designs, reflecting the relative insen-
sitivity to this parameter, as described further
in the Appendix (http://ehp.niehs.nih.gov/
docs/2005/7667/app.pdf). For benzidine and
safrole, there was a notable sex difference,
with high liver tumor incidence observed for
early postnatal exposures of male, but not
female, mice.
Acute-dosing studies of mutagenic chemi-
cals. Acute-dosing studies are available for eight
mutagenic chemicals that were administered to
mice or rats (benzo[a]pyrene, dibenzan-
thracene, DEN, DMBA, dimethylnitrosamine,
ENU, N-methylnitrosourea [MNU], and ure-
thane; Table 1). Except for ENU and MNU,
these compounds require metabolic activation
to their active carcinogenic forms.
Early acute exposures often resulted in
higher potency, with increased early susceptibil-
ities up to 178-fold (ratios of juvenile to adult
potencies range from 0.011 to 178; geometric
mean, 1.5) [Figure 2; Table 4; Supplementary
Table S6 (http://ehp.niehs.nih.gov/docs/
2005/7667/supp.pdf)]. Use of a broader prior
distribution for λ (natural log of the ratio of
juvenile to adult cancer potency) had no effect
on the overall geometric mean (1.5) because
the data highly informed the posterior distrib-
utions, although the range of individual ratios
changed (0.00008–2,055). In studies compar-
ing exposures on specific postnatal days 1, 15,
and 42, general age-dependent declines in sus-
ceptibility of tumor response were observed,
for example, benzo[a]pyrene (liver tumors),
DEN (liver tumors), ENU (liver and nervous
system tumors), and urethane (liver and lung
tumors). Although generally the ratios for
day 1 and day 15 time points were higher
than those for later time points, in several
cases similar tumor incidence was observed at
both of these early times [e.g., ENU-induced
kidney tumors; Supplementary Table S6
(http://ehp.niehs.nih.gov/docs/2005/7667/
supp.pdf)].
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Table 4. Summary of quantitative estimates of ratio of early-life to adult cancer potencies.
No. of Geometric Range of No. of
Dose Tissue chemicals mean ratio ratios ratios
Chemicals with mutagenic mode of action
Repeated 4 10.5 0.12–111 45
Lifetime 3 8.7 0.18–79 6
Combined repeated and lifetime 6 10.4 0.12–111 51
Acute 
Combined (all tissues) 8 1.5 0.01–178 268
Forestomach 3 0.076 0.01–1.9 32
Harderian 2 0.48 0.06–0.8 20
Kidney 2 1.6 0.17–7.1 18
Leukemia 1 5.9 5.1–6.7 2
Liver 5 8.1 0.10–40 70
Lung 7 1.1 0.04–178 77
Lymph 2 1.8 1.1–2.7 3
Mammary
Week 5 vs. week 26 1 7.1 NA 1
Week 2 vs. weeks 5–8 or 26 1 0.071 NA 2
Nerve 2 2.3 0.24–64 10
Nerve (day 1 comparison) 2 10 0.24–64 3
Ovarian 1 0.033 0.01–0.13 3
Reticular tissue 1 6.5 2.0–8.6 2
Thymic lymphoma 1 2.8 1.0–7.9 6
Thyroid 1 0.05 0.03–0.08 2
Uterine/vaginal 1 1.6 0.03–8.6 3
Day 1 (all tissues) 7 1.7 0.01–178 127
Day 15 (all tissues) 3 1.5 0.06–52 74
Chemicals with nonmutagenic mode of action
Repeated 6 2.2 0.06–13 22
Lifetime 5 3.4 0.15–36 38
NA, not applicable.
Although the degree of susceptibility
generally declines with age, there are excep-
tions, such as for pubertal periods of tissue
development. Meranze et al. (1969) reported
8% mammary tumors after a single dose of
DMBA at < 2 weeks of age, 56% if given once
to animals between 5 and 8 weeks of age, and
15% when given once to 26-week-old rats.
Thus, a ratio of 7.1 is obtained when compar-
ing susceptibilities of 5- to 8-week-old and
26-week-old rats compared with a ratio of 0.2
when comparing the exposure at 2 weeks versus
26 weeks [Table 4; Supplementary Table S6
(http://ehp.niehs.nih.gov/docs/2005/7667/
supp.pdf)]. A similar effect was observed
by Russo et al. (1979; Supplementary Table S3
(http://ehp.niehs.nih.gov/docs/2005/7667/
supp.pdf). This observation corresponds well
with pubertal development of the mammary
tissue, with ovarian function commencing
between 3 and 4 weeks [after the < 2-week
time point in the Meranze et al. (1969) study],
and mammary ductal growth and branching
occurring such that it is approximately two-
thirds complete by week 5, consistent with the
5- to 8-week sensitive period of Meranze et al.
(Silberstein 2001).
Early-life susceptibility of different tissues
varies substantially in the acute studies
(Table 4). It should be noted that the target tis-
sues and tissues evaluated vary with chemical,
so the number of chemicals for which data are
available varies for each tissue. Several tissues
have geometric mean ratios > 1, including
kidney, leukemia, liver, lymph, mammary,
nerve, reticular tissue, thymic lymphoma, and
uterus/vagina. Some of these, such as the nerve
and mammary tumors, appear to have a very
specific window of susceptibility, and the ratios
were much higher if the exposure occurred dur-
ing this window. Tissues with mean ratios < 1
include forestomach, harderian gland, ovaries,
and thyroid. Lung has a geometric mean of 1.
Many of the studies produced very high lung
tumor responses regardless of age, so the results
are difficult to interpret, as illustrated by the
dose–response data with urethane in Rogers
(1951), in which the increased early susceptibil-
ity is only apparent when the dose is low. The
large numbers of studies with high lung tumor
responses at all ages are a major contributor to
the differences in the geometric means for the
acute and repeated-dosing studies.
Carcinogens with modes of action other
than mutagenicity. Studies comparing tumors
observed at the same sites after early postnatal
and chronic adult exposures in a single proto-
col were available for six chemicals that do not
act through a mutagenic mode of action
[amitrole, dichlorodiphenyltrichloroethane
(DDT), dieldrin, ethylene thiourea (ETU),
diphenylhydantoin (DPH), polybrominated
biphenyls (PBB); Table 5]. These chemicals
cause tumors through several different, not
necessarily well-defined, modes of action. For
example, thyroid hormone disruption by ETU
causes thyroid tumors; some PBBs act through
the aryl hydrocarbon receptor, whereas other
PBBs are phenobarbital-like pleiotrophic
inducers of liver enzymes and liver tumors.
Three of these studies evaluated only mouse
liver tumors (amitrole, DDT, dieldrin),
whereas the other three evaluated a large num-
ber of tissues in both mice and rats (ETU,
DPH, PBB). No acute-dosing studies were
identified for these agents; such protocols are
generally considered largely nonresponsive for
modes of action other than mutagenicity and
potent estrogenicity (e.g., DES).
For five chemicals (amitrole, DDT, dield-
rin, PBB, DPH), the same tumors were
observed from early and/or adult exposures,
although the studies for amitrole, DDT, and
dieldrin evaluated the animals only for liver
tumors. With ETU, no tumors in mice or rats
were observed after perinatal exposure alone
(except a small, non statistically significant
increase in male rat thyroid tumors), whereas
thyroid tumors were observed in adult rats and
thyroid, liver, and pituitary tumors in adult
mice. Analysis of the incidence of tumors per
time of exposure suggests early–life-stage sus-
ceptibilities. The range of ratios of juvenile to
adult cancer potencies is similar for the
repeated-dosing studies (0.06–13.3; geometric
mean, 2.2; Table 5) and lifetime-dosing studies
[0.15–36; geometric mean, 3.4; Supplementary
Table S5 (http://ehp.niehs.nih.gov/docs/2005/
7667/supp.pdf)]. Use of the broader prior for λ
(natural log of the ratio of juvenile to adult can-
cer potency) gave similar results for the
repeated-dosing studies (0.00043–13.8; geo-
metric mean, 2.9) and a greater variability in
posterior estimates for lifetime studies
(0.001466.4; geometric mean, 7.1). These
ranges are similar to those for chemicals with a
mutagenic mode of action, although the means
and maximums are somewhat lower. Liver
tumors are common to these chemicals. The
range of the magnitudes of liver tumor ratios
also is similar for the repeated-dosing studies
(0.06–13.3; geometric mean, 2.6; Table 5) and
lifetime-dosing studies [0.15–36; geometric
mean, 5.8; Supplementary Table S5 (http://
ehp.niehs.nih.gov/docs/2005/7667/supp.pdf)].
Discussion
The database overall is of modest size (particu-
larly compared with the number of chemicals
that have been studied in adult occupational
epidemiologic studies or chronic bioassays).
Information on different life-stage susceptibili-
ties to cancer risks for humans exists for ioniz-
ing radiation [Appendix (http://ehp.niehs.nih.
gov/docs/2005/7667/app.pdf)]. The effects on
cancer induction by chemical mutagens at dif-
ferent life stages are derived from laboratory
animal studies. Although the induction of
cancer by ionizing radiation and chemical
mutagens are not identical processes, both
involve direct damage to DNA as critical
causal steps in the process. In both cases, the
impacts of early exposure can be greater than
the impacts of later exposures. As indicated in
Table 5 and Supplementary Tables S7–S10
Barton et al.
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Figure 2. Posterior geometric means and 95% confidence intervals for the ratios of juvenile to adult cancer potency for carcinogens acting primarily through a
mutagenic mode of action. (A) Repeated and lifetime exposure studies (geometric mean in black). (B) Acute exposure studies mutagens (geometric mean in
white). The horizontal lines to the left and right of each geometric mean correspond to 95% confidence limits. The vertical solid line represents the geometric
mean; the horizontal solid line represents the 95th percentile; the vertical dotted line is the geometric mean of the 95th percentile. The geometric mean for repeat
and lifetime exposures is 10.4; for acute exposures the geometric mean value is 1.5.
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(http://ehp.niehs.nih.gov/docs/2005/7667/
supp.pdf), A-bomb survivors exhibit different
life-stage dependencies at different tumor sites,
although there are apparent differences at
some sites. However, it is clear that the total
radiation-related tumor incidence showed a
general slow decline with age at exposure. The
mutagenic chemical studies in rodents simi-
larly support a general decline in cancer risk
with age of exposure and similarly show differ-
ences for individual tumor sites. In general,
the first 2 or 3 postnatal weeks in mice and
rats appeared to be the most sensitive.
Analyses of the difference in cancer risk
from exposures during different lifetime periods
ideally need to address both the period of
potential susceptibility and the magnitude of
the susceptibility. Available studies used a vari-
ety of different study designs [Supplementary
Tables S2, S3 (http://ehp.niehs.nih.gov/docs/
2005/7667/supp.pdf)], which can be valuable
because they provide different information.
However, variations in study design can result
in a lack of comparability across chemicals and
can limit information on the consistency of
effects with different chemicals acting through
different modes of action. The acute-dosing
(largely single-dose) studies are valuable because
they involve identical exposures with explicitly
defined doses and time periods demonstrating
that differential tumor incidences arise exclu-
sively from age-dependent susceptibility.
The repeated-dosing studies with exposures
during early postnatal or adult lifetime provide
useful information on the relative impact of
repeated exposures at different life stages and
may be more likely to have exposure occur dur-
ing a window of susceptibility, if there is one.
One notable difference in study designs was
that studies with repeated early postnatal expo-
sures were included in the analysis even if they
also involved earlier maternal and/or prenatal
exposure, whereas studies addressing only pre-
natal exposure were not otherwise a part of this
analysis. The impact of this is limited because it
applies to the lifetime safrole study and the
studies with PBB, DPH, and ETU. Another
notable difference among studies involved the
tissues that were evaluated for tumors: some
studies focused on a single tissue, particularly
liver, whereas others evaluated multiple tissues.
This analysis assumes that the doses animals
received during the different periods of repeated
dose studies were similar. This assumption is a
limitation because these studies involved expo-
sures via lactation, drinking water, diet, or
inhalation, which potentially deliver different
doses at different life stages. However, the range
of the magnitudes of the tumor incidence ratios
of juvenile to adult exposures is similar for the
repeated-dosing studies for chemicals with a
mutagenic mode of action [0.12–111; geo-
metric mean, 11; Tables 2, 4; Supplementary
Table S5 (http://ehp.niehs.nih.gov/docs/2005/
7667/supp.pdf), lifetime-dosing studies
[0.28–79; geometric mean, 8.7; Tables 3, 4;
Supplementary Table S5 (http://ehp.niehs.
nih.gov/docs/2005/7667/supp.pdf)], and
acute-dosing studies [0.01–178; geometric
mean, 1.5; Table 4; Supplementary Tables S5,
S6 (http://ehp.niehs.nih.gov/docs/2005/
7667/supp.pdf)], suggesting that differences in
dosing are not the sole determinant of the
increased incidence of early tumors.
Because these comparisons include chemi-
cals with different tissue specificities, it is useful
to consider the liver as a target organ affected
by all these chemicals; in so doing, even greater
consistency is observed. The range of the mag-
nitudes of the liver tumor potency ratios of
juvenile to adult exposures of mutagenic chem-
icals is similar for the repeated-dosing studies
(geometric mean, 41.8; range, 0.12–111;
Table 2), lifetime-dosing studies (geometric
mean, 14.9; range, 0.47–79; Table 3), and
acute-dosing studies (geometric mean, 8.1;
range, 0.1–40; Table 4). In some cases, win-
dows of susceptibility could occur prenatally.
For example, it is plausible that the major
window of susceptibility for lung is during
in utero development, so sensitivity of the lung
tissue would have been missed in this analysis
(Miller 2004).
The acute studies exposures are largely by
subcutaneous or intraperitoneal injection,
which historically have not been considered rel-
evant routes of environmental exposure for
human cancer risk assessment by the U.S. EPA.
For purposes of comparing age-dependent sus-
ceptibilities with tumor development, these
data are highly relevant. The injection route
typically alters the pharmacokinetic time
courses of the parent compound and the
metabolites compared with oral or other expo-
sures because of altered kinetics of absorption
Susceptibility from early-life exposure
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Table 5. Ratio of early-life to adult cancer potencies for studies with repeated exposures of juvenile and adult animals to nonmutagenic chemicals. 
Ratio of juvenile to adult cancer potency
Species, Geometric
Compound strain Sex Dose Tumor mean 2.5% Median 97.5% References
Amitrole Mice Male 500 Liver 13 5.1 14 30 Vesselinovitch 1983
(B6C3F1) Female 500 Liver 0.14 0.0013 0.18 3.9
DDT Mice Male 150 Liver 1.3 0.0044 2.5 25 Vesselinovitch et al. 1979a
(B6C3F1)
Dieldrin Mice Male 10 Liver 0.75 0.0031 1.2 27 Vesselinovitch et al. 1979a
(B6C3F1)
DPH Rats Male 630 Liver 0.40 0.0024 0.54 16 Chhabra et al. 1993b
(F344/N) Female 630 Liver 0.24 0.0017 0.29 12
Mice Male 210 Liver 1.5 0.0040 2.4 71
(B6C3F1) Female 210 Liver 1.3 0.0056 2.6 15
ETU Rats Male 90 Thyroid 0.37 0.0029 0.61 5.4 Chhabra et al. 1992
(F344/N) Female 90 Thyroid 0.23 0.0018 0.30 7.0
Mice Male 330 Liver 0.091 0.0011 0.12 1.9
(B6C3F1) Female 330 Liver 0.057 0.0010 0.081 0.65
Male 330 Thyroid 0.41 0.0022 0.52 25
Female 330 Thyroid 0.40 0.0024 0.55 16
Male 330 Pituitary 0.32 0.0019 0.38 22
Female 330 Pituitary 0.24 0.0018 0.32 6.9
PBB Rats Male 10 Liver 0.59 0.0041 1.1 6.6 Chhabra et al. 1993a
(F344/N) Female 10 Liver 0.063 0.0009 0.079 1.2
Male 10 Mononuclear cell 0.79 0.0035 1.4 18
leukemia
Female 10 Mononuclear cell 0.21 0.0017 0.28 6.0
leukemia
Mice Male 30 Liver 3.9 1.9 3.9 7.5
(B6C3F1) Female 30 Liver 1.0 0.37 1.05 2.1
and metabolism. However, for these com-
pounds and the systemic organ effects observed,
there are several pharmacokinetic reasons to
believe that the age-dependent trends would
be similar with other routes of exposure.
These compounds are expected to be reason-
ably well absorbed orally, comparable with
injection routes, and largely require metabolic
activation, so partial or complete absence of
first-pass metabolism in the injection studies
would be similar to or underestimate meta-
bolic activation compared with oral exposure.
These studies provide the clearest demonstra-
tions of periods of differential susceptibility
because the exposure rate is constant at the
different ages.
The information on life-stage susceptibil-
ity for chemicals inducing cancers through
other than mutagenic modes of action is more
varied, showing an increase in potency from
perinatal exposure (e.g., PBBs induced liver
tumors in female rats), no effect of combined
perinatal and adult exposure (e.g., DPH liver
tumors in rats), and different tumors from
perinatal exposure versus adult exposure (e.g.,
DES, ascorbate). These variations are likely a
result of the modes of action of these chemi-
cals and the pharmacokinetic differences in
doses during different periods of life.
An important factor that complicates the
interpretation of the results for other modes
of action is that these studies, except those
with DDT and dieldrin, involved dietary
feeding initially to the mother, which poten-
tially could increase or decrease the dose
received by the pups. Because of the maternal
dosing during pregnancy and lactation, the
extent to which offspring received similar
doses during different early and adult life
stages is particularly uncertain for DPH,
ETU, and PBBs. Thus, these studies provide
suggestive evidence that early life stages can
be more sensitive to exposures to chemical
causing cancer through a variety of modes of
action other than mutagenicity. However, the
studies with ETU indicate that this is not
necessarily the case for all modes of action.
No single-dose studies for chemicals with a
nonmutagenic mode of action were evaluated
that were directly comparable with the single-
dose studies with mutagens.
There are important demonstrations of
chemicals causing different tumor types with
early–life-stage exposures compared with those
for adults, for example, tamoxifen and DES
(Carthew et al. 1996, 2000; Gass et al. 1964;
Newbold et al. 1990, 1997). In addition,
studies with in utero exposure to atrazine
(Fenton and Davis 2002), DES, arsenic
(Waalkes et al. 2003), and genistein (Newbold
et al. 2001) indicate that early-life exposures
to compounds can alter susceptibility of
endocrine and reproductive organs. There is
an actively growing database from which to
consider issues of childhood exposure and
cancer for compounds acting through the
estrogen receptor or other mechanisms of
endocrine disruption.
The ability to estimate with any accuracy
the juvenile to adult cancer potency ratio
depends on the experimental design used. The
lifetime design has less ability to distinguish
increased susceptibility from early-life exposure
than the other study designs, as is more thor-
oughly explained with an example in the
Appendix (http://ehp.niehs.nih.gov/docs/
2005/7667/app.pdf).
The proper measure of relative potency of
an exposure in the juvenile period relative to an
exposure in the adult period is the ratio of doses
in the two periods that give the same incidence
of tumors. However, most of the data sets used
in this report contained only one non-control
dose, precluding the extensive dose–response
modeling that would be required to estimate
this ratio of doses. However, this analysis largely
considered chemicals for which a mutagenic
mode of action has been established and for
which a linear, no-threshold dose–response
function is assumed for the low-dose range
being considered for risk assessment, and com-
paring potencies can be shown to be the same
as comparing doses. This is illustrated in the
Appendix (http://ehp.niehs.nih.gov/docs/
2005/7667/app.pdf).
Conclusions
In summary, the existing animal database
supports the conclusion that there can be
greater susceptibility for the development of
tumors as a result of exposures early in life to
chemicals acting through a mutagenic mode
of action. Thus, a risk assessment approach
using estimates from chronic studies with
appropriate modifications to address the
impact of early–life-stage exposure appears fea-
sible. The U.S. EPA has recently released
guidelines for multiplying an extra factor to
the cancer potency for chemicals with a muta-
genic mode of action for exposures that occur
during childhood. The proposed factors are 10
for exposures to children between 0 and
2 years of age, and 3 for exposures to children
between 2 and 15 years of age. The factor
of 10 is based on the data derived from this
analysis, and the factor of 3 represents a
decline in potency expected to occur as chil-
dren mature (U.S. EPA 2005). For chemicals
acting through a nonmutagenic mode of
action, the available data suggest that a range
of approaches needs to be developed over time
for addressing cancer risk estimates from
childhood exposures. Development of such
approaches requires additional research to pro-
vide an expanded scientific basis for their sup-
port, including additional research and the
possible development of new toxicity testing
protocols that consider early–life-stage dosing.
REFERENCES
Anderson LM, Diwan BA, Fear NT, Roman E. 2000. Critical win-
dows of exposure for children’s health: cancer in human epi-
demiological studies and neoplasms in experimental animal
models. Environ Health Perspect 108(suppl 3): 573–594.
Birnbaum LS, Fenton SE. 2003. Cancer and developmental expo-
sure to endocrine disruptors. Environ Health Perspect
111:389–394.
Carlin BP, Louis TA. 2000. Bayes and Empirical Bayes Methods
for Data Analysis. 2nd ed. Boca Raton, FL:Chapman &
Hall/CRC.
Carthew P, Edwards RE, Nolan BM, Martin EA, Heydon T, White
INH, et al. 2000. Tamoxifen induces endometrial and vaginal
cancer in rats in the absence of endometrial hyperplasia.
Carcinogenesis 21:793–797.
Carthew P, Edwards RE, Nolan BM, Martin EA, Smith LL. 1996.
Tamoxifen associated uterine pathology in rodents: rele-
vance to women. Carcinogenesis 17:1577–1582.
Chhabra RS, Bucher JR, Haseman JK, Elwell MR, Kurtz PJ,
Carlton BD. 1993a. Comparative carcinogenicity of poly-
brominated biphenyls with or without perinatal exposure in
rats and mice. Fundam Appl Toxicol 21:451–460.
Chhabra RS, Bucher JR, Haseman JK, Elwell MR, Kurtz PJ,
Carlton BD. 1993b. Comparative carcinogenicity of 5,5-
diphenylhydantoin with or without perinatal exposure in rats
and mice. Fundam Appl Toxicol 21:174–186.
Chhabra RS, Eustis S, Haseman JK, Kurtz PJ, Carlton BD. 1992.
Comparative carcinogenicity of the ethylene thiourea with or
without perinatal exposure in rats and mice. Fundam Appl
Toxicol 18:405–417.
Chieco-Bianchi L, De Benedictis G, Tridente G, Fiore-Donati L.
1963. Influence of age on susceptibility to liver carcinogene-
sis and skin initiating action by urethane in Swiss mice. Br J
Cancer 17:672–680.
Choudari Kommineni VR, Greenblatt M, Vesselinovitch SD,
Mihailovich N. 1970. Urethan carcinogenesis in rats: impor-
tance of age and dose. J Natl Cancer Inst 45(4):687–696.
Cohen SM, Anderson TA, de Oliveira LM, Arnold LL. 1998.
Tumorogenicity of sodium ascorbate in male rats. Cancer
Res 58:2557–2561.
Cohen SM, Garland EM, Cano M, St John MK, Khachab M,
Wehner JM, et al. 1995. Effects of sodium ascorbate, sodium
saccharin and ammonium chloride on the male rat urinary
bladder. Carcinogenesis 16:2743–2750.
Dearfield KL, Auletta AE, Cimino MC, Moore MM. 1991.
Considerations in the U.S. Environmental Protection Agency’s
testing approach for mutagenicity. Mutat Res 258:259–283.
Dearfield KL, McCarroll NE, Protzel A, Stack HF, Jackson MA,
Waters MD. 1999. A survey of EPA/OPP and open literature
on selected pesticide chemicals. II: Mutagenicity and car-
cinogenicity of selected chloroacetanilides and related
compounds. Mutat Res 443:183–221.
De Benedictis G, Maiorano G, Chieco-Bianchi L, Fiore-Donati L.
1962. Lung carcinogenesis by urethane in newborn, suck-
ling, and adult Swiss mice. Br J Cancer 16:686–689.
Della Porta G, Terracini B. 1969. Chemical carcinogenesis in
infant animals. Prog Exp Tumor Res 11:334–363.
Diwan BA, Kasprzak KS, Rice JM. 1992. Transplacental carcino-
genic effects of nickel(II) acetate in the renal cortex, renal
pelvis and adenohypophysis in F344/NCr rats. Carcinogenesis
13:1351–1357.
Diwan BA, Riggs CW, Logsdon D, Haines DC, Olivero OA, Rice
JM, et al. 1999. Multiorgan transplacental and neonatal car-
cinogenicity of 3’azido-deoxythymidine in mice. Toxicol Appl
Pharmacol 161:82–99.
Druckrey H. 1973. Chemical structure and action in transplacental
carcinogenesis and teratogenesis. IARC Sci Publ 4:45–58.
Fenton SE, Davis CC. 2002. Atrazine exposure in utero increases
dimethylbenz[a]anthracene-induced mammary tumor inci-
dence in Long Evans offspring [Abstract]. Toxicol Sci
66(1–2):185.
Fiore-Donati L, De Benedictis G, Chieco-Bianchi L, Maiorano G.
1962. Leukaemogenic activity of urethan in Swiss and AKR
mice. Nature 190:134–139.
Flammang TJ, Von Tungeln LS, Kadlubar FF, Fu PP. 1997. Neonatal
mouse assay for tumorigenicity: alternative to the chronic
rodent bioassay. Regul Toxicol Pharmacol 26:230–240.
Fujii K. 1991. Evaluation of the newborn mouse model for chemi-
cal tumorigenesis. Carcinogenesis 12(8):1409–1415.
Gass GH, Coats D, Graham N. 1964. Carcinogenic dose-response
curve to oral diethylstilbestrol. J Natl Cancer Inst
33:971–977.
Barton et al.
1132 VOLUME 113 | NUMBER 9 | September 2005 • Environmental Health Perspectives
Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M,
et al. 2002. Evaluation of child/adult pharmacokinetic differ-
ences from a database derived from the therapeutic drug lit-
erature. Toxicol Sci 66:185–200.
Ginsberg GL. 2003. Assessing cancer risks from short-term expo-
sures in children. Risk Anal 23:19–34.
Goddard MJ, Krewski D. 1995. The future of mechanistic
research in risk assessment: where are we going and can
we get there from here? Toxicology 102:53–70.
Greenman DL, Highman B, Chen J, Sheldon W, Gass G. 1990.
Estrogen-induced thyroid follicular cell adenomas in C57Bl/6
mice. J Toxicol Environ Health 29:269–278.
Hard GC. 1979. Effect of age at treatment on incidence and type
of renal neoplasm induced in the rat by a single dose of
dimethylnitrosamine. Cancer Res 39:4965–4970.
Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH,
Mittendorf R, et al. 1998. Cancer risk in women exposed to
diethylstilbestrol in utero. JAMA 280:630–634.
Hattis D, Goble R, Russ A, Chu M, Ericson J. 2004. Age-related dif-
ferences in susceptibility to carcinogenesis: a quantitative
analysis of empirical animal bioassay data. Environ Health
Perspect 112(11):1152–1158.
Hayashi M, MacGregor JT, Gatehouse DG, Adler ID, Blakey DH,
Dertinger SD, et al. 2000. In vivo rodent erythrocyte micronu-
cleus assay II. Some aspects of protocol design including
repeated treatments, integration with toxicity testing, and
automated scoring. Environ Mol Mutagen 35:234–252.
Holladay SD, Smialowicz RJ. 2000. Development of the murine
and human immune system: differential effects of immuno-
toxicants depend on time of exposure. Environ Health
Perspect 108(suppl 3):463–473.
Holsapple MP, West LJ, Landreth KS. 2003. Species comparison
of anatomical and functional immune system development.
Birth Defects Res B Dev Reprod Toxicol 68:321–334.
Jurgelski W Jr, Hudson P, Falk HL. 1979. Tissue differentiation
and susceptibility to embryonal tumor induction by ethyl-
nitrosourea in the opossum. Natl Cancer Inst Monogr
51:123–158.
Klein M. 1959. Development of hepatomas in inbred albino mice
following treatment with 20-methylcholanthrene. Cancer Res
19:1109–1113.
Klein M. 1966. Influence of age on induction with urethan of
hepatomas and other tumors in infant mice. J Natl Cancer
Inst 36:1111–1120.
Laib RJ, Bolt HM, Cartier R, Bartsch H. 1989. Increased alkylation
of liver DNA and cell turnover in young versus old rats
exposed to vinyl chloride correlates with cancer susceptibil-
ity. Toxicol Lett 45:231–239.
Law LW. 1940. The production of tumors by injection of a carcino-
gen into the amniotic fluid of mice. Science 91:96–97.
Liebelt RA, Leibelt AG, Lane M. 1964. Hormonal influences on ure-
than carcinogenesis in C3H/f mice. Cancer Res 24:1869–1879.
Maltoni C, Lefemine G, Ciliberti A, Cotti G, Carretti D. 1984.
Experimental research on vinyl chloride carcinogenesis. In:
Archives of Research on Industrial Carcinogenesis (Maltoni
C, Mehlaman MA, eds). Vol 2. Bologna, Italy:Princeton
Scientific Publishers, 1-533.
McCarroll NE, Protzel A, Ioannou Y, Frank Stack HF, Jackson MA,
Waters MD, et al. 2002. A survey of EPA/OPP and open liter-
ature on selected pesticide chemicals. III. Mutagenicity and
carcinogenicity of benomyl and carbendazim. Mutat Res
512:1–35.
McClain R, Keller D, Casciano D, Fu P, MacDonald J, Popp J, et al.
2001. Neonatal mouse model: review of methods and results.
Toxicol Pathol 29(suppl):128–137.
McConnell EE. 1992. Comparative response in carcinogenesis
bioassay as a function of age at first exposure. In:
Similarities and Difference between Children and Adults:
Implications for Risk Assessment (Guzelian P, Henry CJ, Olin
SS, eds). Washington, DC:ILSI Press, 66–78.
Meranze DR, Gruenstein M, Shimkin MB. 1969. Effect of age and
sex on the development of neoplasms in Wistar rats receiv-
ing a single intragastric instillation of 7,12-dimethylbenz(a)-
anthracene. Int J Cancer 4:480–486.
Miller MD, Marty MA, Arcus A, Brown J, Morry D, Sandy M. 2002.
Differences between children and adults: implications for risk
assessment at California EPA. Int J Toxicol 21:403–418.
Miller MS. 2004. Transplacental lung carcinogenesis: molecular
mechanisms and pathogenesis. Toxicol Appl Pharmacol
198(2):95–110.
Morinello EJ, Ham AJL, Ranasinghe A, Nakamura J, Upton PB,
Swenberg JA. 2002a. Molecular dosimetry and repair of
N2,3-ethenoguanine in rats exposed to vinyl chloride. Cancer
Res 62:5189–5195.
Morinello EJ, Koc H, Ranasinghe A, Swenberg JA. 2002b.
Differential induction of N2,3-ethenoguanine in rat brain and
liver after exposure to vinyl chloride. Cancer Res 62(18):
5183–5188.
Murdoch DJ, Krewski D, Wargo J. 1992. Cancer risk assessment
with intermittent exposure. Risk Anal 12:569–577.
Naito M, Naito N, Ito A. 1981. Effect of age at treatment on the
incidence and location of neurogenic tumors induced in
Wistar rats by a single dose of N-ethyl-N-nitrosourea. Gann
72:569–577.
National Research Council. 1993. Pesticides in the Diets of
Infants and Children. Washington, DC:National Academy
Press.
Newbold RR, Banks EP, Bullock B, Jefferson WN. 2001. Uterine
adenocarcinoma in mice treated neonatally with genistein.
Cancer Res 61:4325–4328.
Newbold RR, Bullock BC, McLachlan JA. 1990. Uterine adeno-
carcinoma in mice following developmental treatment with
estrogens: a model for hormonal carcinogenesis. Cancer Res
50:7677–7681.
Newbold RR, Jefferson WN, Padilla-Burgos E, Bullock BC. 1997.
Uterine carcinoma in mice treated neonatally with tamoxifen.
Carcinogenesis 18:2293–2298.
NTP. 1983. Carcinogenesis Bioassay of L-Ascorbic Acid (Vitamin
C) (CAS No. 50-81-7) in F344/N Rats and B6C3F1 Mice (Feed
Study). TR-247. Research Triangle Park, NC:National
Toxicology Program.
NTP. 1999. Toxicology and Carcinogenesis Studies of AZT and
AZT/Gamma-Interferon in B6C3F1 Mice (Gavage Studies).
TR-469. Research Triangle Park, NC:National Toxicology
Program.
NTP. 2003. Home Page. Research Triangle Park, NC:National
Toxicology Program. Available: http://www.ntp.niehs.nih.gov
[accessed 15 December 2003].
Paulsen JE, Steffensen IL, Namork E, Eide TJ, Alexander J. 2003.
Age-dependent susceptibility to azoxymethane-induced and
spontaneous tumorigenesis in the Min/+ mouse. Anticancer
Res 23(1A):259–265.
Peto R, Gray R, Brantom P, Grasso P. 1984. Nitrosamine carcino-
genesis in 5120 rodents: chronic administration of sixteen dif-
ferent concentrations of NDEA, NDMA, NPYR and NPIP in
the water of 4440 inbred rats, with parallel studies on NDEA
alone of the effect of age of starting (3,6, or 20 weeks) and of
species (rats, mice or hamsters). IARC Sci Publ 57:627–665.
Pietra G, Rappaport H, Shubik P. 1961. The effects of carcino-
genic chemicals in newborn mice. Cancer 14:308–317.
Preston DL, Pierce DA, Shimizu Y. 2000. Age-time patterns for
cancer and noncancer excess risks in the atomic bomb sur-
vivors. Radiat Res 154:733–734.
PubMed. 2004. Home Page. Bethesda, MD:National Library of
Medicine. Available: http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi [accessed 22 January 2004]
R Development Core Team. 2003. R: A Language and Environment
for Statistical Computing. Vienna, Austria:R Foundation for
Statistical Computing.
Renwick AG. 1998. Toxicokinetics in infants and children in rela-
tion to the ADI and TDI. Food Addit Contam 15:S17–S35.
Rice JM. 1979. Problems and perspectives in perinatal carcino-
genesis: a summary of the conference. Natl Cancer Inst
Monogr 51:271–278.
Rice JM, Ward JM. 1982. Age dependence of susceptibility to
carcinogenesis in the nervous system. Ann NY Acad Sci
381:274–289.
Rogers S. 1951. Age of the host and other factors affecting the
production with urethane of pulmonary adenomas in mice.
J Exp Med 93:426–449.
Russo J, Wilgus G, Russo IH. 1979. Susceptibility of the mammary
gland to carcinogenesis. I: Differentiation of the mammary
gland as determinant of tumor incidence and type of lesion.
Am J Pathol 96(3):721–736.
Scheuplein R, Charnley G, Dourson M. 2002. Differential sensitiv-
ity of children and adults to chemical toxicity. I: Biological
basis. Regul Toxicol Pharmacol 35:429–447.
Silberstein GB. 2001. Tumour-stromal interactions: role of the
stroma in mammary development. Breast Cancer Res 3:
218–223.
Slikker W III, Mei N, Chen T. 2004. N-Ethyl-N-nitrosourea (ENU)
increased brain mutations in prenatal and neonatal mice but
not in the adults. Toxicol Sci 81(1):112–120.
Terracini B, Testa M. 1970. Carcinogenicity of a single administra-
tion of N-nitrosomethylurea: a comparison newborn and
5-week-old mice and rats. Br J Cancer 24(3):588–598.
Terracini B, Testa MC, Cabral JR, Rossi L. 1976. The roles of age at
treatment and dose in carcinogenesis in C3Hf/Dp mice with a
single administration of N-nitroso-N-methylurea. Br J Cancer
3(4):427–439.
Toth B. 1968. A critical review of experiments in chemical carcino-
genesis using newborn animals. Cancer Res 28(4):727–738.
U.S. EPA. 1986. Guidelines for mutagenicity risk assessment. Fed
Reg 51:34006–34012.
U.S. EPA. 1991. Pesticide Assessment Guidelines, Subdivision F,
Hazard Evaluation: Human and Domestic Animals, Series 84,
Mutagenicity, Addendum 9. EPA-540/09-91-122; NTIS Publ no.
PB91-158394. Washington, DC:U.S. Environmental Protection
Agency, Office of Pesticides and Toxic Substances.
U.S. EPA. 1996. Comparison of the Effects of Chemicals with
Combined Perinatal and Adult Exposure vs Adult Only
Exposure in Carcinogenesis Bioassays. Washington, DC:
U.S. Environmental Protection Agency, Office of Pesticide
Programs.
U.S. EPA. 2000. Atrazine Health Assessment: Part B: Hazard
Assessment and Review of Available Studies. Washington,
DC:U.S. Environmental Protection Agency, Office of
Pollution, Pesticides and Toxic Substances.
U.S. EPA. 2005. Draft Supplemental Guidance for Assessing
Susceptibility from Early-Life Exposure to Carcinogens.
EPA/630/R-03/003F. Washington, DC:U.S. Environmental
Protection Agency.
Vesselinovitch SD. 1983. Perinatal hepatocarcinogenesis. Biol
Res Pregnancy Perinatol 4(1):22–25.
Vesselinovitch SD, Koka M, Mihailovich N, Rao KVN. 1984.
Carcinogenicity of diethylnitrosamine in newborn, infant, and
adult mice. J Cancer Res Clin Oncol 108:60–65.
Vesselinovitch SD, Kyriazis AP, Milailovich N, Rao KVN. 1975a.
Conditions modifying development of tumors in mice at vari-
ous sites by benzo(a)pyrene. Cancer Res 35:2948–2953.
Vesselinovitch SD, Rao KV, Mihailovich N. 1975b. Factors modu-
lating benzidine carcinogenicity bioassay. Cancer Res
35(10):2814–2819.
Vesselinovitch SD, Rao KV, Mihailovich N. 1979a. Neoplastic
response of mouse tissues during perinatal age periods. NCI
Monogr 51:239–250.
Vesselinovitch SD, Rao KV, Mihailovich N. 1979b. Transplacental
and lactational carcinogenesis by safrole. Cancer Res
39(11):4378–4380.
Vesselinovitch SD, Rao KV, Mihailovich N, Rice JM, Lombard LS.
1974. Development of broad spectrum of tumors by ethylni-
trosourea in mice and the modifying role of age, sex, and
strain. Cancer Res 34(10):2530–2538.
Waalkes MP, Ward JM, Diwan BA. 2003. Transplacental carcino-
genicity of inorganic arsenic in the drinking water: induction
of hepatic, ovarian, pulmonary, and adrenal tumors in mice.
Toxicol Appl Pharmacol 186:7–17.
Walters MA. 1966. The induction of lung tumours by the injection
of 9,10-dimethyl-1,2-benzanthracene (DMBA) into newborn,
suckling, and young adult mice. Br J Cancer 20:148–160.
Waters MD, Stack HF, Jackson MA. 1999. Short-term tests for
defining mutagenic carcinogens. IARC Sci Publ 146:499–536.
Whysner J, Williams GM. 1996. Saccharin mechanistic data and
risk assessment: urine composition, enhanced cell prolifera-
tion, and tumor promotion. Pharmacol Ther 71:225–252.
Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N,
et al. 2003. Hormonal and dietary modulation of mammary
carcinogenesis in mouse mammary tumor virus-c-erbB-2
transgenic mice. Cancer Res 63(10):2425–2433.
Susceptibility from early-life exposure
Environmental Health Perspectives • VOLUME 113 | NUMBER 9 | September 2005 1133
